Nevro Corporation has announced the US Food and Drug Administration (FDA) approval and limited market release of HFX iQ with HFX AdaptivAI—a responsive, personalised pain management platform powering the HFX iQ spinal cord stimulation (SCS) system.
Building on a foundation of landmark evidence, clinical research and big data, Nevro claims that HFX AdaptivAI is “the only technology with artificial intelligence (AI) to provide patients suffering from chronic pain with an unprecedented level of personalised, responsive pain relief”.
“HFX AdaptivAI is a significant leap forward in pain management,” said Usman Latif (University of Kansas Health System, Kansas City, USA). “Drawing from landmark evidence and big data, this technology has the potential to offer patients a faster and more sustainable approach to pain relief. HFX AdaptivAI is on the right path to make a lasting impact on how we manage chronic pain and improve patient outcomes.”
A recent press release from Nevro states that HFX AdaptivAI offers:
- Relief and beyond—HFX AdaptivAI is engineered to maximise pain relief over time by continuing to optimise therapy even when pain relief over 50% has been achieved
- Bipole interlacing—proprietary technology creates customised therapy programmes in real time using direct patient input
- Smart Power—through therapy optimisation, advanced Smart Power technology allows patients to charge their device as little as six times per year
- Enhanced real-time insights—HFX AdaptivAI technology gathers real-time quality of life (QoL) metrics and device data, enabling more impactful patient-clinician interactions, with this information also helping patients to report pain relief in significantly less time than with traditional programming
- Advanced proactive remote monitoring—with the launch of HFX AdaptivAI, physicians will have the ability to remotely monitor each of their patients’ pain journeys in real time through Nevro’s healthcare provider portal
“Chronic pain is a dynamic, biopsychosocial human condition unique to each individual,” said David Caraway, Nevro’s chief medical officer. “To effectively treat suffering—as perceived by each patient—therapies must be personalised based on the changing experience of pain. Only HFX AdaptivAI seeks to engage with the patient and personalise the SCS therapy in real time using evidence based on algorithms and multi-dimensional metrics of pain relief, function, and satisfaction.”
“Nevro is further establishing its position as the leading developer of data-driven solutions for pain management through the launch of HFX iQ with HFX AdaptivAI,” added Kevin Thornal, the company’s chief executive officer and president. “HFX AdaptivAI delivers personalised pain relief, utilising AI, and leveraging millions of data points and 10 years of innovation and patient care. We believe this new solution is a major milestone, and it demonstrates our dedication to freeing patients from the burden of chronic pain through evidence-based therapies that transform patients’ lives. Importantly, HFX AdaptivAI puts patients in control of their pain relief while, at the same time, providing physicians the ability to monitor their patient’s pain journey—closing the loop that matters.”
Nevro expects to launch its full market release of HFX iQ with HFX AdaptivAI in the USA in the fourth quarter of 2024, as stated in the company’s recent press release.
